Navigation Links
Tosedostat OPAL Study Final Results Selected for Oral Presentation at the 2011 American Society of Hematology (ASH) Annual Meeting
Date:12/6/2011

rather than intercalation with DNA -- pixantrone alkylates DNA -- forming stable DNA adducts with particular specificity for CpG-rich, hyper-methylated sites. These structural differences resulted in significantly enhanced anti-lymphoma activity compared to doxorubicin in preclinical models. In addition, the structural motifs on anthracycline-like agents that are responsible for the generation of oxygen free radicals and the formation of toxic drug-metal complexes have also been modified in pixantrone in an effort to prevent the binding of iron and perpetuation of superoxide production -- both of which are the putative mechanism for anthracycline induced acute cardiotoxicity. These novel pharmacologic differences may allow re-introduction of anthracycline-like potency in the treatment of relapsed/refractory diffuse large lymphoma without unacceptable rates of cardiotoxicity.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable.

Sign up for email alerts and get RSS feeds at our Web site, http://www.CellTherapeutics.com/investors_alert.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of pixantrone and tosedostat include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with pixantrone and tosedostat in particular including, without limitation, the potential failure of pixantrone to prove safe and effective for the treatment of NHL and/or other tumors as determined by the U.S. Food and Drug Administration (the "FDA") and/or the European Medicines Agency (th
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmathene Announces Publication of Phase I Study Results for Anthrax Anti-toxin Valortim®
2. Aethlon Medical Announces Approval and Initiation of Cancer Research Study to Target Tumor-Secreted Exosomes
3. New Study Shows AFECTAIR® Significantly Improved Delivery of Nitric Oxide Under Simulated Neonatal Ventilatory Conditions
4. First Patient Enrolled in Therakos Phase Two Study for Treatment of Graft-versus-Host Disease
5. New Gene Study of ADHD Points to Defects in Brain Signaling Pathways
6. RECITAL Study Presents Excellent Outcomes and Rapid Patient Recovery With Revolutionary Femoral Access Procedure
7. Auxilium Pharmaceuticals, Inc. Announces First Patient Dosed in XIAFLEX® Study for Frozen Shoulder Syndrome
8. Ceregene Completes Enrollment of Second Phase 2 Study of CERE-120 for the Treatment of Parkinsons Disease
9. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Combination Study of MM-121 and Multiple Anticancer Therapies in Patients with Advanced Solid Tumors
10. BioMarin Initiates Phase 2 Study for GALNS in Patients Under Five Years of Age With MPS IVA
11. New Study Points to Novel Mechanism by Which Tumors Escape Recognition by the Immune System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... de octubre de 2014  PneumRx, Inc. ( ... la pulmonología intervencional, anunció hoy la conclusión de ... meses antes de lo programado. El Estudio Clínico RENEW ... de investigación (IDE) aprobada por la FDA (Administración ... espiral de reducción de volumen pulmonar PneumRx RePneu, ...
(Date:10/20/2014)... , Oct. 20, 2014  ResMed (NYSE: ... the ResMed Data Exchange program, a comprehensive suite ... equipment (HME) and other health care providers. ... access to critical patient information. It integrates valuable ... and U-Sleep™ patient management platforms with customers, in-house ...
(Date:10/20/2014)... 20, 2014  AnaptysBio, Inc., a leader in ... announced the appointment of Marco Londei , ... lead the preclinical and clinical development of AnaptysBio,s ... pleased to welcome Dr. Londei to AnaptysBio,s executive ... and Chief Executive Officer of AnaptysBio. "Dr. Londei,s ...
Breaking Medicine Technology:PneumRx concluye inscripción en prueba fundamental RENEW 2PneumRx concluye inscripción en prueba fundamental RENEW 3ResMed Launches ResMed Data Exchange 2AnaptysBio Appoints Dr. Marco Londei to Newly Created Chief Development Officer Position Clinical Immunologist to Lead AnaptysBio's Pipeline Advancement 2
... REYKJAVIK, Iceland, July 1 The ... several new common,single-letter variants in the sequence of the human ... a multinational consortium of scientists,led by a team from deCODE ... 50,000 patients and control participants from fourteen countries.,It is published ...
... announces that it has reached the halfway mark (1,600 patients) ... G auging R esponsiveness with A V erifyNow(R) ... nd S afety). The trial is specifically designed ... for patients who are poor responders to clopidogrel (Plavix(R)). ...
Cached Medicine Technology:deCODE-led Megastudy Finds New Genetic Clues to Causes of Schizophrenia 2deCODE-led Megastudy Finds New Genetic Clues to Causes of Schizophrenia 3deCODE-led Megastudy Finds New Genetic Clues to Causes of Schizophrenia 4deCODE-led Megastudy Finds New Genetic Clues to Causes of Schizophrenia 5Accumetrics, Inc. Announces GRAVITAS Trial 50 Percent Enrolled 2
(Date:10/20/2014)... Allegheny General Hospital’s (AGH) Cardiovascular Institute is offering ... a damaged mitral valve as the heart continues to ... Abbott Vascular , is designed to treat degenerative ... which the heart’s mitral valve leaflets fail to close ... left ventricle into the left atrium. The heart must ...
(Date:10/20/2014)... 2014 ASCNYC (ascnyc.org) is a ... New Yorkers living with HIV/AIDS and other chronic ... recovery and self-sufficiency. Each year, ASCNYC spotlights selected ... through their tireless efforts. , Savills Studley ... has been selected as this year’s honoree for ...
(Date:10/20/2014)... T.E.N., a technology and information ... that William H. Murray, renowned author and industry ... Leadership Award winner. Presented annually, the ISE® Luminary ... leader and industry practitioner for his or her ... information security industry. , Formerly with IBM, Murray ...
(Date:10/20/2014)... D.C. (PRWEB) October 20, 2014 Zereana Jess-Huff, ... crowned Mrs. Maryland 2014 on a platform to think outside ... scars, and uses her position to raise awareness about women’s ... awareness for breast cancer. You say the color pink and ... I know for a fact that it has not been ...
(Date:10/20/2014)... Kennewick, WA (PRWEB) October 20, 2014 ... new workflow management software application. The new module ... ensure patients receive full life-cycle quality care. , This ... to others within their practice, attach a to-do item ... see fit, and even set up reoccurring reminders for ...
Breaking Medicine News(10 mins):Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 3Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 2Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 4Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 2Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 3Health News:My Clients Plus Announces New Workflow Management Software 2
... IQ for HealthVault Empowers Patients to Orchestrate Health ... ... Kryptiq, the leading provider,of next generation healthcare connectivity solutions, ... offices,and patients using Microsoft(R) HealthVault(TM), at the 2008 HIMSS,(Healthcare Information ...
... Calif., Feb. 25 Hyperion,Therapeutics, Inc. today announced ... Phase 2 clinical trial of AMMONUL(R) (sodium phenylacetate ... III or IV hepatic,encephalopathy (HE). The randomized, double-blind ... of AMMONUL versus standard of care in,hospitalized adults. ...
... CHARLOTTE, N.C., Feb. 25 MedCath Corporation,(Nasdaq: MDTH ... at the Raymond James 29th Annual Institutional Investors,Conference held ... Orlando,Fla., MedCath,s senior management will give its presentation ... will be web cast live over the Internet,via MedCath,s ...
... 25 Omron Healthcare, Inc. has,announced Bob ... officer. With,an extensive background in sales, Kondraske ... profit growth in their mainstay business,categories: blood ... medical. Kondraske,s experience as a proven,business leader ...
... Va., Feb. 25 Meddius, an emerging,provider ... integration technology and professional services to assist ... system,which provides hospitals with a Web-based, automated ... associated infections (HAIs). The announcement,was made today ...
... enhanced to support multifaceted hospital, environments; provide more secure ... ... Feb. 25 HIMSS ,08 -- Omnicell,Inc. (Nasdaq: ... acute,healthcare facilities, today introduced its OptiFlex(TM) SS 9.0 supply,chain ...
Cached Medicine News:Health News:Kryptiq and Microsoft to Showcase Unprecedented Connectivity Between Consumers and Their Doctors at HIMSS '08 2Health News:Kryptiq and Microsoft to Showcase Unprecedented Connectivity Between Consumers and Their Doctors at HIMSS '08 3Health News:Hyperion Therapeutics Announces Enrollment of First Patient in Phase 2 Clinical Trial in Patients With Hepatic Encephalopathy 2Health News:Hyperion Therapeutics Announces Enrollment of First Patient in Phase 2 Clinical Trial in Patients With Hepatic Encephalopathy 3Health News:Omron Healthcare Names New Chief Operating Officer Bob Kondraske 2Health News:Meddius Signs Agreement to Deliver an Integration Platform for Premier's SafetySurveillor(TM) 2Health News:Hospital Environments Increase Staff Efficiency and Patient Safety With Omnicell OptiFlex(TM) SS 9.0 2Health News:Hospital Environments Increase Staff Efficiency and Patient Safety With Omnicell OptiFlex(TM) SS 9.0 3
... The LT-Cage device ... balance with significantly less ... endplates. Medtronic Sofamor Danek's ... designed to easily and ...
3D Cranial is the most widely used surgical navigation software. Navigate with confidence and ease with displayed Zone of Accuracy and several fully automated features. 3D Cranial offers seamless int...
Designed for the effective positioning of patients during spinal surgery, the frame gives the surgeon a remarkably simple and versatile surgical tool....
Adjust-A-Tip cautery....
Medicine Products: